Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial

OBJECTIVES: The aim of this trial is to investigate the safety and clinical efficacy of passive immunization therapy through Hyperimmune anti-COVID-19 Intravenous Immunoglobulin (C-IVIG: 5% liquid formulation), on severe and critically ill patients with COVID-19. TRIAL DESIGN: This is a phase I/II s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Shaukat, Luxmi, Shobha, Anjum, Fatima, Muhaymin, Sheikh Muhammad, Uddin, Syed Muneeb, Ali, Ayesha, Ali, Mir Rashid, Tauheed, Sohaib, Khan, Mujtaba, Bajwa, Mohsin, Baig, Saif Ullah, Shalim, Elisha, Ahmed, Iqra, Khan, Abdul Samad, Quraishy, Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604645/
https://www.ncbi.nlm.nih.gov/pubmed/33138867
http://dx.doi.org/10.1186/s13063-020-04839-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604645/
https://www.ncbi.nlm.nih.gov/pubmed/33138867
http://dx.doi.org/10.1186/s13063-020-04839-5

Ejemplares similares